Abstract
At a maximum follow up of 8 years (median 5 years 6 months) in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxifen daily for 2 years. This advantage is independent of menopausal status, stage, grade and ER status. Log hazard rate analysis fails to demonstrate a rebound effect on stopping the drug and suggests that more prolonged treatment might further improve results.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Consortia
Additional information
'Nolvadex' is a property of Imperial Chemical Industries plc.
Members of the Steering Committee were: M. Baum (Chairman), D.M. Brinkley, J.A. Dosset, K. McPherson, I.M. Jackson, R.D. Rubens, F.G. Smiddy, B.A. Stoll, A.J. Wilson, I.H. Birch & M.K. Palmer.
Rights and permissions
About this article
Cite this article
Analysis at Eight Years by 'Nolvadex'., Adjuvant Trial Organisation.. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57, 608–611 (1988). https://doi.org/10.1038/bjc.1988.138
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.138
This article is cited by
-
The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer
Current Atherosclerosis Reports (2023)
-
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Nature Reviews Clinical Oncology (2022)
-
Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform
BMC Cancer (2021)
-
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
Current Treatment Options in Oncology (2018)
-
Status of adjuvant endocrine therapy for breast cancer
Breast Cancer Research (2014)